Clinical Trial Update: Pacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating pacritinib as a JAK/STAT pathway inhibitor in refractory colorectal cancer was terminated, with results posted in May 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Pacritinib (pacritinib)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Colorectal Cancer | Phase 2 | Status: TERMINATED | Results posted: 2017-05-01